Most Read

Nexus Pharmaceuticals chief commercial officer Omair Ahmed said: “The approval of generic Arsenic Trioxide injection continues to show Nexus’s commitment in providing access to affordable critical-need generic injectables.

This recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Bristol-Myers Squibb melanoma and genitourinary

One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from

Study results, published online in Cell Reports, showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges.

The financing was led by Hillhouse Capital Management and Quan Capital, and included Bay City Capital, Surveyor Capital (a Citadel company), Ping An Ventures, Taiho Ventures LLC, ArrowMark

The FDA and the Company have agreed to meet in-person on January 31, 2019 to discuss this matter. Remoxy is the proposed trade name for a new type

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. CRISPR

OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment. Harpoon’s existing investors MPM Capital, Oncology

Now available by prescription in pharmacies across the US, NOCDURNA provides adults with a fast-acting, effective treatment that targets the kidneys, the underlying cause of NP. The sublingual